Too late in the day and tomorrow is Friday..But $ALTH looks to be heading to 1.80 real quick : http://t.co/5Ucf0wN0

#Downgrades: $AMAG $VPHM $AMGN $ALTR $CMA $DCT $MFLX $ALTH $PG $RL $CLR $FST $PNRA $AVT $ARW $SIRI $AB $MMR $TXRH $LLL $JCI $HRS $LEA $STI

$ALTH - While we think $SGEN inroads into CTCL will impinge temporarily on Folotyn sales, this was a decent presentation. #JPM12

$ALTH Folotyn sales $50.5M in 2011, expect it "to grow rapidly in years to come." Assuming no sales increase, cash lasts through 2015....

$ALTH has patent protection thru 2017 w/ potential 5-yer Hatch-Waxman through 2022. Some use patents 2022. #JPM12

$ALTH calling 2011 their true first launch year, implying they weren't prepared with sales structure the prior 5 quarters. #JPM12

$ALTH claims PTCL 2nd line market is $400M, but footnotes, "This is not a Folotyn forecast." Yup. (Says Global market is $800M) #JPM12

$ALTH showing an interesting slide of all the PTCL subtypes. Using it as a marketing tool. Also shown at ODAC panel. #JPM12

$ALTH claims 10,000 patient PTCL and subsets r/r market for Folotyn #JPM12

RT @adamfeuerstein: Oops. Still groggy. $ALTH Folotyn Q4 sales $11M ex-certain one-timers, not $15.4M. Thx to @jimmysil for pointing out